Robert Ćhilton - Concepedia

Author

Robert Ćhilton

The University of Texas Health Science Center at San Antonio ORCID

Also Known As

Chilton R, R Chilton, R J Chilton, R. Chilton, R. J. Chilton, R.J. Chilton, ROBERT CHILTON, ROBERT J. CHILTON, Robert Chilton, Robert J Chilton

254

Publications

5.4K

Citations

H-Index

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Texas Diabetes Institute South Texas Veterans Health Care System Boehringer Ingelheim (Germany)Harvard University

RĆ

About

Robert Ćhilton is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	2.2K
2	Public Health	2	2	346
3	Engineering	1	1	11
4	Health Sciences	1	1	15
5	Allergy Medicine	1	1	152

Robert Ćhilton

Publications

3.4K

Citations

H-Index

Page 1

	Year	Citations
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Sonia S. Anand, Jackie Bosch, John W. Eikelboom, The Lancet ThrombosisCardiovascular DiseaseStrokeMedicinePlacebo-controlled Trial	2017	855
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Stuart J. Connolly, John W. Eikelboom, Jackie Bosch, The Lancet ThrombosisCardiovascular DiseaseAtherosclerosisMedicineCoronary Artery Disease	2017	749
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes Robert Ćhilton, I. Tikkanen, Christopher P. Cannon, Diabetes Obesity and Metabolism	2015	494
SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study Muhammad Abdul‐Ghani, Stefano Del Prato, Robert Ćhilton, Diabetes Care HypertensionHeart FailureCardiovascular PharmacologyPharmacotherapyPreventive Cardiology	2016	297
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus Ian J. Neeland, Darren K. McGuire, Robert Ćhilton, Diabetes and Vascular Disease Research	2015	160
Potentiated anaphylaxis in patients with drug-induced beta-adrenergic blockade Robert L. Jacobs, Geoffrey Rake, Donald C. Fournier, Journal of Allergy and Clinical Immunology AsthmaDrug HypersensitivityDrug IntoleranceAllergy MedicineMedicine	1981	152
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Muhammad Abdul-Ghani, Ralph A. DeFronzo, Stefano Del Prato, Diabetes Care	2017	145
Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes Geoffrey D. Clarke, Carolina Solis‐Herrera, Marjorie Molina‐Wilkins, Diabetes Care	2017	63
Pathophysiology of coronary heart disease: a brief review. Robert Ćhilton PubMed HyperlipidemiaCoronary Artery DiseasePublic HealthCardiovascular Disease PathogenesisAtherosclerosis	2004	49
Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension Robert Ćhilton, Ilkka Tikkanen, Uwe Hehnke, Diabetes Obesity and Metabolism	2017	46

Page 1